ROC analysis with TCGA plus GTEx datasets indicated that the diagnostic value of SERINC2 was high (AUC > 90%) in thyroid cancers (Figure 4F. Survival analysis using GEPIA2 suggested that the high expression of SERINC2 is associated with worse DFS (Figure 4G), but the expression of SERINC2 is not associated with overall survival (Figure S3). Here, SERINC2 is linked to thyroid gland carcinoma.